Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Göhler

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
The Journal of Cell Biology|January 19, 2011
ATR-mediated phosphorylation of DNA polymerase η is needed for efficient recovery from UV damageThomas Göhler, Simone Sabbioneda, Catherine M Green, et al.
DNA Repair|March 21, 2008
PTIP/Swift is required for efficient PCNA ubiquitination in response to DNA damageThomas Göhler, Ivan M Munoz, John Rouse, et al.
Nucleic Acids Research|February 22, 2005
Mutant p53 proteins bind DNA in a DNA structure-selective modeThomas Göhler, Stefan Jäger, Gabriele Warnecke, et al.
The Journal of Biological Chemistry|June 19, 2003
Analysis of p53 "latency" and "activation" by fluorescence correlation spectroscopy. Evidence for different modes of high affinity DNA bindingJulian Wölcke, Maurice Reimann, Martin Klumpp, et al.
The Journal of Biological Chemistry|August 13, 2002
Specific interaction of p53 with target binding sites is determined by DNA conformation and is regulated by the C-terminal domainThomas Göhler, Maurice Reimann, Dimitry Cherny, et al.
BMC Cancer|July 27, 2017
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)Thomas Decker, Friedrich Overkamp, Siegfried Rösel, et al.
Breast Cancer Research and Treatment|July 6, 2017
Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer: results from the MaTox projectHans-Jürgen Hurtz, Hans Tesch, Thomas Göhler, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 24, 2026
Effectiveness and safety of pegylated filgrastim (Pelgraz®) for the prevention of febrile neutropenia during cancer chemotherapy in all-day practice in GermanyTilman Steinmetz, Peter Jungberg, Dagmar Guth, et al.
The Journal of Cell Biology|June 7, 2006
Excess Mcm2-7 license dormant origins of replication that can be used under conditions of replicative stressAnna M Woodward, Thomas Göhler, M Gloria Luciani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2017
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT StudyTom M Ganten, Rudolf E Stauber, Eckardt Schott, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
The Journal of Cell Biology|January 19, 2011
ATR-mediated phosphorylation of DNA polymerase η is needed for efficient recovery from UV damageThomas Göhler, Simone Sabbioneda, Catherine M Green, et al.
DNA Repair|March 21, 2008
PTIP/Swift is required for efficient PCNA ubiquitination in response to DNA damageThomas Göhler, Ivan M Munoz, John Rouse, et al.
Nucleic Acids Research|February 22, 2005
Mutant p53 proteins bind DNA in a DNA structure-selective modeThomas Göhler, Stefan Jäger, Gabriele Warnecke, et al.
The Journal of Biological Chemistry|June 19, 2003
Analysis of p53 "latency" and "activation" by fluorescence correlation spectroscopy. Evidence for different modes of high affinity DNA bindingJulian Wölcke, Maurice Reimann, Martin Klumpp, et al.
The Journal of Biological Chemistry|August 13, 2002
Specific interaction of p53 with target binding sites is determined by DNA conformation and is regulated by the C-terminal domainThomas Göhler, Maurice Reimann, Dimitry Cherny, et al.
BMC Cancer|July 27, 2017
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)Thomas Decker, Friedrich Overkamp, Siegfried Rösel, et al.
Breast Cancer Research and Treatment|July 6, 2017
Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer: results from the MaTox projectHans-Jürgen Hurtz, Hans Tesch, Thomas Göhler, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 24, 2026
Effectiveness and safety of pegylated filgrastim (Pelgraz®) for the prevention of febrile neutropenia during cancer chemotherapy in all-day practice in GermanyTilman Steinmetz, Peter Jungberg, Dagmar Guth, et al.
The Journal of Cell Biology|June 7, 2006
Excess Mcm2-7 license dormant origins of replication that can be used under conditions of replicative stressAnna M Woodward, Thomas Göhler, M Gloria Luciani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2017
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT StudyTom M Ganten, Rudolf E Stauber, Eckardt Schott, et al.
Pageof 3